BrightSpring Health Services, Inc. Common Stock 2026 Jefferies Healthcare Services and Technology Conference

Yeah. Thanks, Brian. Great to be here.

Sure. Let's see. It's already September. Can't believe the kids have been back in school for a couple of weeks, but we continue to have a really productive year here as we work our way through Q3. Very pleased with the performance across the breadth of the organization. At our company, we really position ourselves as a leading provider of home and community healthcare. That's a very big market with a lot of demand for services in home and community settings. We think that's a great place to be. Within home and community healthcare, we target a number of pharmacy and provider businesses that we feel like all have a lot of support behind them and where we can differentiate and be very successful.

On the pharmacy side, our specialty pharmacy infusion and home and community pharmacy, and on the provider side, home health hospice and rehab, where we just have really excellent teams running these businesses. There's a lot of benefit that we get from being one organization. We just continue to try to drive quality and innovate within our markets and do our best for patients, so that they can receive great services in optimal settings.

Yeah. As I said before, we like the breadth of the markets we're in. We can really leverage our infrastructure across all of these. What we do from a quality process perspective, from an HR perspective, from an M&A perspective, from a sales and marketing perspective, it's a very similar playbook for all of our pharmacy and provider businesses that we try to apply. Something that we've been focused on now for, hard to believe, about 10 years, is just driving broad-based growth and really wanting to get to double-digit growth at a minimum, but doing so on the back of quality and on the back of really good technology and people. Broad-based growth across organizations, across the markets we really like is something we focus on all the time.

Within our specialty business, generics is one of five or six different growth drivers just within our specialty business. We're pleased that when a drug does convert from a brand to generic, which is a good thing ultimately for the healthcare system from a cost perspective, we try to drive the utilization as much as we can and still offer really great services for our referral sources, our physicians, and our patients. We try to play a leading role where when those events happen, inevitably there's always brands that are going to be converting to generic. That's how the life cycle works. We've built up a sales force of over 250 people at this point, where we try to be a great partner to all the referral sources out there, thousands of referral sources for these special patients every day.

We just try to be the best partner we can through these events. There were a number of more significant brands going generic in the last couple of years. There's been a couple conversions this year, and as we look to next year, there's two or three of the bigger brands converting generically next year as well. You can't always perfectly predict or just the way it happens. You can't always say that XYZ happens every quarter, so it can tend to be a little bit lumpy. But as you look over a year or a period of time, you're just always going to have several of these events every year, and we've tried to position the organization to be as effective in those conversion processes as possible with how we partner with doctors and patients and manufacturers out there through them.

We look forward to next year where we expect several more of these larger brands are going to convert.

Yeah, I think thankfully for patients, there's just a ton of innovation that continues to occur from the biotech firms and our manufacturing partners, which is a wonderful thing. Your prognosis today with certain conditions is far different than even five years ago, and in some cases, even a year ago. So, when these dynamic new therapies come to market, we do our best to be a value-add provider for biotech and pharma through a lot of different mechanisms, whether it's data analytics reporting, whether it's patient support through the insurance verification process, whether it's patient education, serving as a hub for patients, providing third-party logistics services. Those are things we really try to do in addition to just fundamental service quality and great fulfillment support for the patient, being their fastest for them.

These things are all elements of what manufacturers and biotech partners need to help get great clinical outcomes for their patients, which is so important to them. Oncology has been the space we've been the deepest in for coming up on 15 years now. As time has gone by, based on our capabilities in oncology and our partnerships with manufacturers, we've expanded into other areas. There's even some cardiology drugs now, some kidney drugs, but rare and orphan therapies is another one. I think a number of pharmacies that really focus on these niche areas do a nice job. We continue to try to do everything we can from a partnership perspective in these pharma services areas.

It's resulted in about 20 new launches a year where we've been an exclusive or one of two in a pharmacy network, and we see that frequency continuing for the future. There's a very healthy innovation pipeline thanks to the work of a lot of great companies out there, and we've just continued to try to position ourselves as a provider of choice. I point to something like a Net Promoter Score, from doctors and from patients, which is pulsed every quarter from third-party sources, and it's not unusual for us to get 100 there on a Net Promoter Score, which is very difficult to do. So extremely proud of the team with how seriously they take these therapies for all the constituents.